UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~____________________~~_________________

FORM 8-K

~~____________________~~_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of ~~the~~Report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): August 11, 2025

~~Date of Report (Date of earliest event reported): June 11, 2025~~_______________________________

~~____________________~~Compass Therapeutics, Inc.

COMPASS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

~~____________________~~_______________________________

Delaware	001-39696	82-4876496
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

(617) 500-8099

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

~~____________________~~_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CMPX	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.0702. ~~Submission~~Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition.

On ~~June~~August 11, 2025, Compass Therapeutics, Inc. ~~(the~~issued ~~“Company”) held~~a ~~its~~press ~~Annual~~release ~~Meeting~~announcing offinancial ~~Stockholders. The final~~ results for ~~each of~~ the ~~matters~~quarter ~~submitted~~and tosix amonths ~~vote~~ended ofJune ~~stockholders~~30, ~~at the meeting are set forth below~~2025. A ~~more~~copy ~~detailed description~~ of ~~each proposal is set forth in~~ the ~~Company’s~~press ~~definitive~~release ~~proxy~~is ~~statement~~furnished onas ~~Form DEF~~Exhibit ~~14A,~~99.1 ~~filed~~to ~~with~~this ~~the~~report ~~U.S. Securities~~ and ~~Exchange~~incorporated ~~Commission~~herein onby ~~April 29, 2025~~reference.

~~Proposal~~Item No7. 101. ~~Election~~Regulation ofFD ~~Directors~~Disclosure. The stockholders elected the three Class II nominees for director to serve until the Company’s 2028 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified, by the votes set forth in the table below:

					Broker Non-
Name	For		Withheld		votes
Carl L. Gordon, Ph.D., C.F.A.		80,657,849		4,244,164		29,432,541
Philip J. Ferneau, M.B.A. J.D.		58,301,963		26,600,050		29,432,541
James P. Boylan, M.B.A.		83,645,920		1,256,093		29,432,541

A copy of the slides presented during the second quarter earnings call is furnished as exhibit 99.2 and the Company’s August 2025 corporate presentation is furnished as Exhibit 99.3 to this Current Report on Form 8-K and is incorporated herein by reference.

~~Proposal~~The Noinformation contained in this Item 7.01 2(including Exhibit 99.2) ~~Ratification~~is being furnished and shall not be deemed “filed” for purposes of ~~Appointment~~Section 18 of ~~Independent Registered~~the ~~Public~~Exchange ~~Accounting~~Act, ~~Firm.~~or ~~The~~otherwise ~~stockholders~~subject ~~ratified~~to the ~~appointment~~liabilities of ~~CohnReznick,~~that ~~LLP~~section asand ~~the~~shall ~~Company’s~~not ~~independent registered~~be ~~public~~deemed ~~accounting~~incorporated ~~firm~~by ~~for~~reference in any filing under the ~~year~~Securities ~~ending~~Act ~~December~~or ~~31,~~the ~~2025~~Exchange Act, byexcept ~~the~~as ~~votes~~shall be expressly set forth inby ~~the~~specific ~~table~~reference ~~below:~~in such filing.

					Broker Non-
For	Against		Abstained		votes
114,283,119		28,647		22,788		0

Item 9.01. Financial Statements and Exhibits.

~~SIGNATURE~~(d) Exhibits

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit No.		Exhibit

99.1		Press Release dated August 11, 2025 (furnished pursuant to Item 2.02)
99.2		Corporate presentation - Earnings Call August 11, 2025
99.3		Corporate presentation of Compass Therapeutics, Inc. dated August 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

	Compass Therapeutics, Inc.
Date: June 12, 2025	By:	/s/ NEIL LERNER
		Neil Lerner
		Chief Accounting Officer

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Compass Therapeutics, Inc.


Date: August 11, 2025	By:	/s/ Neil Lerner
		Neil Lerner
		Chief Accounting Officer

Filing Compare · Compass Therapeutics, Inc.